Lyell Immunopharma trial: 77% complete response rate
LyFE is expected to have capacity to manufacture more than 3,000 CAR T-cell doses per year.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
8-K
Rhea-AI Filing Summary
Lyell Immunopharma, Inc. reported third-quarter results and updated ronde-cel data. Among 44 efficacy-evaluable patients in the 3L+ PiNACLE trial, the overall response rate was 91% and the complete response rate was 77%. Median duration of complete response and median progression-free survival were not reached; the estimated continued complete response rate was 92% at six months and 75% at 12 months. No Grade ≥ 3 CRS was observed; Grade ≥ 3 ICANS was reported in 9% of patients.
PiNACLE pivotal data are expected in mid-2027, with a BLA submission expected in the second half of 2027. Lyell completed LYL273 technology transfer to its LyFE Manufacturing Center in September; further clinical data and an FDA End-of-Phase 1 meeting are expected in 2027. Lyell announced an $80.0 million private placement in November. Cash, cash equivalents and marketable securities were $194.0 million as of September 30, 2026; together with net placement proceeds, they are expected to fund operations into 2028.
Third-quarter net loss was $45.5 million, versus $38.8 million a year earlier; non-GAAP net loss was $41.3 million versus $29.1 million. Revenue was $3,000, compared with $15,000. Research and development expense was $40.9 million, up from $28.2 million, while general and administrative expense was $9.3 million, down from $10.7 million.
0 points · 0 major0 major · 2 points
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Positive
- None.
Negative
- Moderate pointQuarterly net loss reached $45.5 million, versus $38.8 million a year earlier.
- Minor pointQuarterly revenue was $3,000, compared with $15,000 a year earlier.
8-K Event Classification
2 items: 2.02, 9.01
2 items
Item 2.02
Results of Operations and Financial Condition
Financial
Disclosure of earnings results, typically an earnings press release or preliminary financials.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, or exhibit attachments filed with this report.
Key Figures
Overall response rate: 91%
Complete response rate: 77%
Grade ≥ 3 ICANS: 9%
+5 more
8 metrics
Overall response rate
91%
Among 44 efficacy-evaluable patients in the 3L+ PiNACLE trial
Complete response rate
77%
Among 44 efficacy-evaluable patients in the 3L+ PiNACLE trial
Grade ≥ 3 ICANS
9%
Reported in the 3L+ PiNACLE trial
Net loss
$45.5 million
Third quarter 2026; $38.8 million in the same period of 2025
Non-GAAP net loss
$41.3 million
Third quarter 2026; $29.1 million in the same period of 2025
Revenue
$3,000
Third quarter 2026; $15,000 in the same period of 2025
Cash, cash equivalents and marketable securities
$194.0 million
As of September 30, 2026
Private placement
$80.0 million
Announced in November 2026
Key Terms
overall response rate, progression-free survival, Biologics License Application, Regenerative Medicine Advanced Therapy, +1 more
5 terms
overall response rate medical
"overall response rate was 91%"
Overall response rate is the percentage of patients in a clinical study whose measurable disease shrinks or disappears after receiving a treatment. Investors watch it like a product’s “hit rate” because higher response rates can signal a drug’s effectiveness, boost chances of regulatory approval and market demand, and affect a company’s future revenue prospects, similar to how a higher batting average suggests a more reliable player.
progression-free survival medical
"median progression-free survival"
Progression-free survival is the length of time during and after a treatment that a patient's disease does not get worse, measured from the start of treatment until the disease shows measurable signs of progression or the patient dies. Investors care because longer progression-free survival in clinical trials often signals that a drug is effective, improving chances of regulatory approval, market adoption, and revenue potential—think of it as a stopwatch showing how long a therapy can keep the illness at bay.
Biologics License Application regulatory
"submission of a Biologics License Application (BLA)"
A biologics license application is a formal request submitted to regulatory authorities seeking approval to market a new biological medicine, such as vaccines or treatments made from living organisms. It is a comprehensive review process that evaluates the safety, effectiveness, and manufacturing quality of the product. For investors, receiving approval signals that a biological therapy can be sold to the public, potentially leading to revenue growth and market success.
Regenerative Medicine Advanced Therapy regulatory
"Regenerative Medicine Advanced Therapy (RMAT) designation"
Regenerative Medicine Advanced Therapy (RMAT) is a U.S. regulatory designation for cell, gene, and tissue‑based therapies intended to treat serious or life‑threatening conditions; it gives developers a “fast lane” with more frequent agency interaction and eligibility for accelerated review pathways. For investors, an RMAT label signals that a therapy may reach market faster and face less regulatory uncertainty than a standard program, which can raise the potential value and reduce timeline risk—though it is not a guarantee of approval.
non-GAAP net loss financial
"Non-GAAP net loss, which excludes non-cash stock-based compensation"
Non-GAAP net loss is a company’s reported loss that has been adjusted by removing certain costs or one-time items that the company believes hide its core operating performance. Think of it like looking at a household budget but excluding an unusual repair or sale; it can show a clearer view of everyday results, which helps investors judge ongoing profitability, but it can also omit real expenses so it should be compared with the standard GAAP loss.
Earnings Snapshot
Revenue: $3,000
Third quarter ended September 30, 2026
Revenue
$3,000
Compared with $15,000 in the same period of 2025
Net loss
$45.5 million
Compared with $38.8 million in the same period of 2025
Non-GAAP net loss
$41.3 million
Compared with $29.1 million in the same period of 2025
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What is LYEL's PiNACLE-H2H trial comparing?
PiNACLE-H2H is a Phase 3 randomized controlled trial comparing ronde-cel with investigator’s choice of axicabtagene ciloleucel or lisocabtagene maraleucel in second-line relapsed/refractory large B-cell lymphoma; its primary endpoint is event-free survival.
What manufacturing capacity does LyFE have?
LyFE has commercial launch capability and is expected to have capacity to manufacture more than 3,000 CAR T-cell doses per year.
AI-generated analysis. How Rhea-AI works. Not financial advice.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
______________________________________________
FORM 8-K
______________________________________________
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): November 4, 2026
______________________________________________
(Exact name of Registrant as Specified in Its Charter)
______________________________________________
| (State or Other Jurisdiction of Incorporation) | (Commission File Number) | (IRS Employer Identification No.) | ||||||||||||
| (Address of Principal Executive Offices) | (Zip Code) | |||||||||||||
Registrant’s Telephone Number, Including Area Code: 650 695-0677
(Former Name or Former Address, if Changed Since Last Report)
Not Applicable
______________________________________________
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |||||
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |||||
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |||||
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) | |||||
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||||||||||||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company o
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o
Item 2.02 Results of Operations and Financial Condition.
On November 4, 2026, Lyell Immunopharma, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended September 30, 2026. A copy of the press release is attached hereto as Exhibit 99.1.
The information in this Item 2.02, including the attached Exhibit 99.1, is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing made by the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
| Exhibit Number | Description | |||||||
| 99.1 | Press Release Dated November 4, 2026 | |||||||
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) | |||||||
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
| Lyell Immunopharma, Inc. | |||||||||||
| Date: | November 4, 2026 | By: | /s/ MARK MELTZ | ||||||||
| Mark Meltz | |||||||||||
| General Counsel and Corporate Secretary | |||||||||||
Exhibit 99.1
Lyell Immunopharma Reports Business Highlights and Financial Results for the Third Quarter 2026
•Announced updated clinical data in more than 80 patients from the ongoing PiNACLE pivotal trial in patients with 3L+ R/R LBCL and from the Phase 1/2 trial 2L cohort of ronde-cel in abstracts accepted for presentation at ASH 2026.
•The overall response rate was 91% and the complete response rate was 77% among 44 efficacy-evaluable patients in the 3L+ PiNACLE trial. The median duration of complete response and median progression-free survival were not reached, with an estimated continued complete response rate of 92% at six months and 75% at 12 months. No Grade ≥ 3 CRS was observed and Grade ≥ 3 ICANS was reported in 9% of patients.
•PiNACLE pivotal data disclosure is on track for mid-2027, with BLA submission expected to follow in the second half of 2027.
•Completed technology transfer of LYL273 to the LyFE Manufacturing Center™ following FDA review of improved manufacturing process and updated analytical methods; additional clinical data and End-of-Phase 1 meeting with FDA expected in 2027.
•Announced private placement financing of $80.0 million with participation from a high-quality syndicate of existing and new investors.
•Approximately $194.0 million in cash, cash equivalents and marketable securities as of September 30, 2026, together with net proceeds from the private placement, expected to fund operations into 2028.
SOUTH SAN FRANCISCO, Calif., November 4, 2026 -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a late-stage clinical company advancing a pipeline of next-generation chimeric antigen receptor (CAR) T-cell therapies for patients with cancer, today reported financial results and business highlights for the third quarter ended September 30, 2026.
“The updated ronde-cel data accepted for presentation at ASH further strengthen our conviction in ronde-cel’s potential to meaningfully improve outcomes for patients with large B-cell lymphoma,” said Lynn Seely, M.D., President and Chief Executive Officer of Lyell. “The high rates of very durable complete responses achieved by ronde-cel in both the second- and third- or later-line settings, including in patients with high-risk primary refractory disease, clearly showcase the next-generation potential of ronde-cel. With two pivotal trials underway, including our single-arm pivotal PiNACLE trial expected to complete enrollment by year end and on track for pivotal data and BLA submission in the second half of 2027, we are now focusing on preparation for commercialization. We are also continuing to advance LYL273 following the successful transfer of manufacturing to LyFE, as we work to determine the recommended Phase 2 dose and optimize the safety management plan ahead of our planned End-of-Phase 1 discussions with the FDA in 2027.”
Third Quarter Updates and Recent Business Highlights
Rondecabtagene Autoleucel (ronde-cel): A next-generation dual-targeting CD19/CD20 CAR T-cell product candidate designed to increase complete response rates and prolong the duration of response as compared to approved CD19‑targeted CAR T-cell therapies for the treatment of relapsed/refractory large B-cell lymphoma
Ronde-cel is an autologous CAR T-cell product candidate under evaluation in two pivotal trials in patients with relapsed/refractory (R/R) large B-cell lymphoma (LBCL) in the third- or later-line (3L+) setting (PiNACLE) and the second-line (2L) setting (PiNACLE‑H2H). A multi-cohort dose-escalation, dose-expansion Phase 1/2 trial is also ongoing. Ronde-cel targets B cells that express either CD19 or CD20 with a true ‘OR’ logic gate to achieve full potency at either target and is manufactured with a process that enriches for CD62L-positive cells to generate more naïve and central memory CAR T cells with enhanced stemlike features and antitumor activity. The U.S. Food and Drug Administration (FDA) has granted ronde-cel Regenerative Medicine Advanced Therapy (RMAT) and Fast Track designations for the treatment of adults with R/R diffuse LBCL in the 3L+ setting and also RMAT designation for the treatment of LBCL in the 2L setting.
•Lyell announced today updated clinical data from the ongoing PiNACLE pivotal trial in patients with 3L+ R/R LBCL and from the Phase 1/2 trial 2L cohort of ronde-cel in patients with R/R LBCL in two abstracts accepted for presentation at the 68th American Society of Hematology Meeting and Exposition (ASH 2026), taking place December 12–15, 2026.
•The PiNACLE pivotal single-arm trial, a seamless expansion of the 3L+ cohort in the Phase 1/2 multi-cohort trial, is ongoing. Pivotal data are expected in mid-2027 with submission of a Biologics License Application (BLA) to the FDA expected to follow in the second half of 2027. The primary endpoint of the trial is overall response rate, including an evaluation of duration of response.
•PiNACLE-H2H, the first-of-its-kind Phase 3 randomized controlled trial evaluating ronde-cel versus investigator’s choice of axicabtagene ciloleucel or lisocabtagene maraleucel in patients with R/R LBCL in the 2L setting, continues to enroll patients. The trial’s primary endpoint is event-free survival.
LYL273: A next-generation guanylyl cyclase C (GCC)-targeted CAR T-cell product candidate for the treatment of relapsed/refractory metastatic colorectal cancer (mCRC) and other GCC-expressing cancers
LYL273 is a GCC-targeted CAR T-cell product candidate enhanced with CD19 CAR expression and controlled cytokine release, designed to improve CAR T-cell expansion, immune cell infiltration and cancer cell killing in the hostile solid tumor microenvironment. The FDA granted LYL273 Fast Track designation for the treatment of mCRC.
•In September 2026, Lyell completed the planned technology transfer for LYL273 to its LyFE Manufacturing Center™ (LyFE) in Bothell, Washington, following FDA review of an improved manufacturing process and updated analytical methods. LyFE is implementing the improved manufacturing process and updated analytical methods to enhance manufacturing performance and increase capacity. The Phase 1/2 clinical trial of LYL273 in patients with R/R mCRC continues to enroll patients, including dosing of patients with LYL273 manufactured using the new process at LyFE, with the goal of determining the recommended Phase 2 dose and optimizing the safety management plan.
•Additional clinical data from the Phase 1/2 trial of LYL273 in patients with 3L+ R/R mCRC and an End-of-Phase 1 meeting with the FDA are expected in 2027.
Corporate Update
•In November 2026, the Company announced a private placement of $80.0 million with participation from a high-quality syndicate of existing and new investors. The proceeds are expected to extend cash runway into 2028, beyond anticipated BLA submission for ronde-cel in the second half of 2027, as well as updated clinical data from the GCC-targeted LYL273 program for patients with mCRC.
Third Quarter 2026 Financial Results
Lyell reported a net loss of $45.5 million for the third quarter ended September 30, 2026, compared to a net loss of $38.8 million for the same period in 2025. The $6.7 million increase in net loss was primarily due to a $12.7 million increase in research and development expenses driven by increased clinical trial activity, partially offset by a $4.0 million prior-year loss on the securities purchase agreement put/call that did not recur. Non‑GAAP net loss, which excludes non-cash stock-based compensation, non-cash expenses related to the change in the estimated fair value of the securities purchase agreement put/call relating to the Company’s July 2025 private placement transaction and success payment liabilities, increased by $12.2 million to $41.3 million for the third quarter ended September 30, 2026, compared to $29.1 million for the same period in 2025, primarily due to increased clinical trial activity and lower interest income.
GAAP and Non-GAAP Operating Expenses
•Research and development (R&D) expenses were $40.9 million for the third quarter ended September 30, 2026, compared to $28.2 million for the same period in 2025. The $12.7 million increase was primarily due to a $12.2 million increase in research activities, collaborations and outside services due to increased clinical trial activity. Non‑GAAP R&D expenses, which exclude non-cash stock-based compensation, for the third quarter ended September 30, 2026 were $38.8 million compared to $26.2 million for the same period in 2025.
•General and administrative (G&A) expenses were $9.3 million for the third quarter ended September 30, 2026, compared to $10.7 million for the same period in 2025, primarily due to lower professional services expenses. Non‑GAAP G&A expenses, which exclude non-cash stock‑based compensation, for the third quarter ended September 30, 2026 were $6.9 million compared to $7.5 million for the same period in 2025.
A discussion of non-GAAP financial measures, including reconciliations of the most comparable U.S. generally accepted accounting principles (GAAP) measures to non‑GAAP financial measures, is presented below under “Non-GAAP Financial Measures.”
Cash, cash equivalents and marketable securities
Cash, cash equivalents and marketable securities as of September 30, 2026 were $194.0 million compared to $247.2 million as of December 31, 2025. Lyell believes that its current cash, cash equivalents and marketable securities
balances, together with the net proceeds from the $80.0 million private placement in November 2026, will be sufficient to meet working capital and capital expenditure needs into 2028.
About Lyell Immunopharma, Inc.
Lyell is a late-stage clinical company advancing a pipeline of next-generation CAR T-cell therapies for patients with hematologic malignancies and solid tumors. To realize the potential of cell therapy for cancer, Lyell utilizes a suite of technologies to arm CAR T cells with enhancements needed to drive durable tumor cytotoxicity and achieve consistent and long-lasting clinical responses, including the ability to resist exhaustion, maintain qualities of durable stemness and function in the hostile tumor microenvironment. LyFE has commercial launch capability and is expected to have the capacity to manufacture more than 3,000 CAR T-cell doses per year. To learn more, please visit www.lyell.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements expressed or implied in this press release include, but are not limited to, statements regarding: Lyell’s intention to present updated ronde-cel results at ASH 2026; Lyell’s belief that its current cash, cash equivalents and marketable securities, together with the net proceeds from the private placement in November 2026, will be sufficient to meet working capital and capital expenditure needs into 2028; Lyell’s expectations around the progress of the PiNACLE and PiNACLE-H2H trials, including the expected timing for release of additional and pivotal data from the PiNACLE trial, the use of pivotal data from the PiNACLE trial to support a BLA submission to the FDA in the second half of 2027 and other expectations around enrollment and regulatory submissions; Lyell’s planned activities in anticipation of commercialization; Lyell’s expectations around the progress of the U.S. Phase 1/2 trial for LYL273, including the expected timing for release of additional clinical data from this trial, determination of the recommended Phase 2 dose, optimization of the safety management plan, implementation of the improved manufacturing process and updated analytical methods and an End-of-Phase 1 FDA meeting; the anticipated benefits of Orphan Drug, RMAT and Fast Track designations for ronde-cel and Fast Track designation for LYL273; the capability of LyFE to manufacture drug supply through potential commercial launch and its expected manufacturing capacity; the potential clinical benefits and therapeutic potential of Lyell’s product candidates; and other statements that are not historical fact. These statements are based on Lyell’s current plans, objectives, estimates, expectations and intentions, are not guarantees of future performance and inherently involve significant risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, but are not limited to, risks and uncertainties related to: Lyell operates in a rapidly evolving industry and has a limited operating history; Lyell’s ability to successfully develop, manufacture and commercialize product candidates or its experiencing significant delays in doing so; Lyell’s dependence on the enrollment and retention of patients in its current and planned clinical trials for its product candidates; the potential for results of Lyell’s research, nonclinical studies or earlier clinical trials to not be predictive of future results; clinical development involving a lengthy and expensive process with uncertain outcomes; Lyell’s product candidates and technologies being based on novel technologies that are unproven and may not result in approvable or marketable products; Lyell facing substantial competition in a rapidly changing industry, which may result in others discovering, developing or commercializing products before or more successfully than it does; Lyell’s ability to obtain and maintain sufficient intellectual property protection for its product candidates; the complexity of manufacturing cellular therapies; Lyell’s ability to manufacture drug products for its clinical trials itself and any potential delays in further qualifying or in receiving regulatory approvals for any manufacturing facility or product candidates or in expanding its manufacturing capacity; Lyell’s reliance on third parties; implementation of Lyell’s strategic plans for its business and product candidates and Lyell’s realization of the expected benefits of such plans; the potential reduction of Lyell’s cash resources and fluctuations in Lyell’s operating results and financial condition as a result of Lyell’s milestone, royalty and success payment obligations; the sufficiency of Lyell’s capital resources and need for additional capital to achieve its goals; and other risks, including those described under the heading “Risk Factors” in Lyell’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2026, being filed with the Securities and Exchange Commission today. Forward-looking statements contained in this press release are made as of this date, and Lyell undertakes no duty to update such information except as required under applicable law.
Lyell Immunopharma, Inc.
Unaudited Selected Consolidated Financial Data
(in thousands)
Statement of Operations Data:
| Three Months Ended September 30, | Nine Months Ended September 30, | ||||||||||||||||||||||
| 2026 | 2025 | 2026 | 2025 | ||||||||||||||||||||
Revenue | $ | 3 | $ | 15 | $ | 9 | $ | 30 | |||||||||||||||
| Operating expenses: | |||||||||||||||||||||||
| Research and development | 40,898 | 28,172 | 117,026 | 106,476 | |||||||||||||||||||
| General and administrative | 9,297 | 10,687 | 28,428 | 34,519 | |||||||||||||||||||
| Other operating income, net | (1,897) | (1,591) | (5,552) | (648) | |||||||||||||||||||
| Impairment of long-lived assets | — | — | — | 1,443 | |||||||||||||||||||
| Total operating expenses | 48,298 | 37,268 | 139,902 | 141,790 | |||||||||||||||||||
| Loss from operations | (48,295) | (37,253) | (139,893) | (141,760) | |||||||||||||||||||
| Interest income, net | 1,905 | 3,266 | 6,283 | 10,404 | |||||||||||||||||||
Other income (expense), net | 861 | (4,859) | 19,173 | (2,369) | |||||||||||||||||||
| Total other income (loss), net | 2,766 | (1,593) | 25,456 | 8,035 | |||||||||||||||||||
| Net loss | $ | (45,529) | $ | (38,846) | $ | (114,437) | $ | (133,725) | |||||||||||||||
Balance Sheet Data:
| As of September 30, | As of December 31, | ||||||||||
| 2026 | 2025 | ||||||||||
| Cash, cash equivalents and marketable securities | $ | 193,988 | $ | 247,220 | |||||||
| Property and equipment, net | $ | 28,531 | $ | 34,771 | |||||||
| Total assets | $ | 273,854 | $ | 340,052 | |||||||
| Total stockholders’ equity | $ | 192,721 | $ | 248,202 | |||||||
Non-GAAP Financial Measures
To supplement our financial results and guidance presented in accordance with GAAP, we present non-GAAP net loss, non-GAAP R&D expenses and non-GAAP G&A expenses. Non‑GAAP net loss excludes non-cash stock-based compensation expense, non-cash expenses related to the change in the estimated fair value of success payment liabilities and the change in the estimated fair value of our securities purchase agreement put/call asset. Non‑GAAP R&D and G&A expenses exclude non-cash stock-based compensation expense from GAAP R&D and G&A expenses. We believe that these non‑GAAP financial measures, when considered together with our financial information prepared in accordance with GAAP, can enhance investors’ and analysts’ ability to meaningfully compare our results from period to period, and to identify operating trends in our business. We have excluded stock-based compensation expense, changes in the estimated fair value of success payment liabilities and the change in the estimated fair value of our securities purchase agreement put/call asset from our non‑GAAP financial measures because they are gains and charges that may vary significantly from period to period as a result of changes not directly or immediately related to the operational performance for the periods presented. We also regularly use these non‑GAAP financial measures internally to understand, manage and evaluate our business and to make operating decisions. These non-GAAP financial measures are in addition to, and not a substitute for or superior to, measures of financial performance prepared in accordance with GAAP. In addition, these non‑GAAP financial measures have no standardized meaning prescribed by GAAP and are not prepared under any comprehensive set of accounting rules or principles and, therefore, have limits in their usefulness to investors. We encourage investors to carefully consider our results under GAAP, as well as our supplemental non-GAAP financial information, to more fully understand our business.
Lyell Immunopharma, Inc.
Unaudited Reconciliation of GAAP to Non-GAAP Net Loss
(in thousands)
| Three Months Ended September 30, | Nine Months Ended September 30, | ||||||||||||||||||||||
| 2026 | 2025 | 2026 | 2025 | ||||||||||||||||||||
| Net loss - GAAP | $ | (45,529) | $ | (38,846) | $ | (114,437) | $ | (133,725) | |||||||||||||||
| Adjustments: | |||||||||||||||||||||||
| Change in the estimated fair value of securities purchase agreement put/call | — | 4,029 | (17,561) | 4,029 | |||||||||||||||||||
| Stock-based compensation expense | 4,514 | 5,232 | 13,341 | 16,260 | |||||||||||||||||||
| Change in the estimated fair value of success payment liabilities | (263) | 461 | (1,015) | 221 | |||||||||||||||||||
Net loss - Non-GAAP(1) | $ | (41,278) | $ | (29,124) | $ | (119,672) | $ | (113,215) | |||||||||||||||
(1)There was no income tax effect related to the adjustments made to calculate non-GAAP net loss because of the full valuation allowance on our net deferred tax assets for all periods presented.
Lyell Immunopharma, Inc.
Unaudited Reconciliation of GAAP to Non-GAAP Research and Development Expenses
(in thousands)
| Three Months Ended September 30, | Nine Months Ended September 30, | ||||||||||||||||||||||
| 2026 | 2025 | 2026 | 2025 | ||||||||||||||||||||
Research and development - GAAP | $ | 40,898 | $ | 28,172 | $ | 117,026 | $ | 106,476 | |||||||||||||||
| Adjustments: | |||||||||||||||||||||||
| Stock-based compensation expense | (2,124) | (2,004) | (6,499) | (6,687) | |||||||||||||||||||
| Research and development - Non-GAAP | $ | 38,774 | $ | 26,168 | $ | 110,527 | $ | 99,789 | |||||||||||||||
Lyell Immunopharma, Inc.
Unaudited Reconciliation of GAAP to Non-GAAP General and Administrative Expenses
(in thousands)
| Three Months Ended September 30, | Nine Months Ended September 30, | ||||||||||||||||||||||
| 2026 | 2025 | 2026 | 2025 | ||||||||||||||||||||
| General and administrative - GAAP | $ | 9,297 | $ | 10,687 | $ | 28,428 | $ | 34,519 | |||||||||||||||
| Adjustments: | |||||||||||||||||||||||
| Stock-based compensation expense | (2,390) | (3,228) | (6,842) | (9,573) | |||||||||||||||||||
| General and administrative - Non-GAAP | $ | 6,907 | $ | 7,459 | $ | 21,586 | $ | 24,946 | |||||||||||||||
Contact:
Lyell Investor Relations
IR@lyell.com